Drug Profile
Ulcerative colitis therapeutic - Eli Lilly and Company
Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ulcerative colitis
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Ulcerative-colitis in USA
- 20 Jul 2015 Phase-I clinical trials in Ulcerative colitis in USA (unspecified route)